Ocrevus and rituximab had similar infection rates in MS
Key Takeaway
People with MS taking Ocrevus or rituximab had similar infection and relapse rates.
What They Found
Researchers compared infection and relapse rates across MS treatments in Sweden. People taking ocrelizumab (Ocrevus) or rituximab had more infections than people taking other MS drugs. They also had fewer relapses than people taking other MS drugs. Infection rates were similar between Ocrevus and rituximab. Relapse rates were also similar between the two drugs.
Who Should Care and Why
The study looked at people with MS receiving treatment in Sweden. It compared Ocrevus, rituximab, and other MS drugs. The results may matter to people weighing infection risk alongside relapse rates. Serious infections, infections diagnosed at a hospital, and antibiotic use were included. The findings describe what happened during treatment in Sweden, not what would happen to any one person.
Important Considerations
You should know this was an observational study, which compared treatment records rather than assigning drugs to people. It included 16,872 treatment episodes, not necessarily that many people. The abstract does not say whether other differences between treatment groups affected the results.
AI-generated summary — for informational purposes only, not medical advice
Categories:
You May Also Like
11/1/2026
Researchers compared blood from people with childhood-onset MS and healthy volunteers. They found DN
Read More
11/1/2026
In 24 people with severe MS, stem cell treatment lowered signs of inflammation and nerve damage for
Read More
11/1/2026
A review of 49 studies finds special brain scans can detect MS-related inflammation, but scan method
Read More
11/1/2026
In a study of 294 pregnancies, MS flare-ups were uncommon after pausing two treatments. Learn what t
Read More
10/16/2026
Two rare conditions can look like MS. An Italian study links certain treatments to more time without
Read More
10/15/2026
Researchers suggest adding a drug after stem cell transplant to help keep MS from returning. Learn h
Read MoreUnderstanding MS Research
Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Annals of neurology often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.
However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.
By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.